Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户：subae

【摘要】

：

【作者】

：

Edward B.Garon Natasha B.Leighl Naiyer A.Rizvi George R.Blumenschein Jr. Ani Sarkis Balmanoukian Joseph Paul Eder Jonathan Wade Goldman Rina Hui Jean-Charles Soria Tara C.Gangadhar Jong-Mu Sun Amita P

【机构】

：

David Geffen School of Medicine, University of California Los Angeles School of Medicne,Los Angeles,

【出处】

：

第十七届全国临床肿瘤学大会暨2014年CSCO学术年会

【发表日期】

：

2014年11期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells and PD-L 1 and PD-L2 on tumor cells in pts with previously-treated, progressive locally advanced or metastatic NSCLC.

其他文献

CL-385319, a potential influenza entry inhibitor, protects mice from lethal H1N1 infection combined

Objective: Influenza is one of the major global plagues, and to date there are only two types of effective antiviral agents against it in clinic (M2 inhibitors and NA inhibitors).

会议

Avian influenza a virusCL-385319Andrographolide

Isoform-specific glucuronidation of morusin, a highly anti-HIV activitiy constituent from the root b

Morusin is a prenylated flavonoid that was firstly isolated from the root bark of Morus alba L., possesses anti-HIV, anti-oxidant, anti-inflammatory and anti-tumor activities.

会议

MorusinUGTmetabolismliver

Anti-influenza A virus and anti-inflammatory metabolites isolated from marine associated microorgani

Background: Filamentous microorganisms such as filamentous fungi and bacteria are represented as one of the major sources for bioactive compounds, especially for lead identification in medical science

会议

Fungi and actinimycessecondary metabolitesanti-infectious and anti-inflammato

Suramin Inhibits Semen-Derived Amyloid Fibril Formation and Blocks Fibril-Mediated Enhancement of HI

Semen-derived enhancer of viral infection(SEVI), made up of residues 248-286 of prostatic acidic phosphatase (PAP248-286), is composed of amyloid fibrils that can greatly enhance HIV-1 infectivity and

会议

SuraminSEVIHIV-1amyloid fibril

Dendrobine inhibits influenza A virus replication by restraining virus nucleoprotein function

Influenza virus remains to pose a direct threat to human beings and society for causing severe epidemics of respiratory illness, and highlights an urgent need for new anti-influenza drugs.

会议

nucleoproteininfluenza A virusdendrobine

The immunoproteasome inhibitor PR-957 reactives latent HIV through P-TEFb

Although the current combined anti-retroviral therapy (cART) could successfully control HIV viraemia in infected patients under the detectable level, it fails to completely eradicate the pathogen.

会议

latent HIVPR-957Proteasome inhibitorP-TEFb

低剂量131I治疗低刺激性Tg、不伴有远处转移的高危分化型甲状腺癌

目的:目前尚无低剂量131I用于治疗低刺激性Tg、不伴有远处转移的高危分化型甲状腺癌的相关研究,本研究旨在探讨低剂量131I在这部分人群中的清甲效果.方法:纳入本回顾性研究的标准为:1)年龄＞18岁;2)分化型甲状腺癌全切术后;3)T4分期(术中肉眼可见甲外侵犯),任何N分期;4)清甲治疗前刺激性Tg≤5ng/ml;5)无远处转移的证据;6)TgAb≤46IU/ml.这部分患者在TSH刺激状态下(

会议

Safety and efficacy of the Asian subgroup of patients (pts) with EGFR-TKI-resistant advanced non-sma

Objective: AZD9291 is an oral, potent, irreversible EGFR-TKI, selective for sensitizing (EGFRm+) and T790M resistance mutations, currently under investigation in an ongoing Phase Ⅰ study of pts with E

会议

Dacomitinib versus Erlotinib in 2nd-/3rd-line NSCLC (ARCHER 1009 Global Phase Ⅲ trial):Outcomes in C

Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun

会议

Tumorigenic potential of circulating tumor cells in pulmonary venous blood from Non-Small Cell Lung

Objective: To explore the clinical value and biological characteristics of circulating tumor cells (CTCs) in pulmonary vein (CTCs-pv) from patients with surgically resected non-small cell lung cancer

会议

Safety and clinical activity of pembrolizumab (pembro, MK-3475) in previously-treated patients (pts)

其他学术论文